CoChat

Bringing Light to the Dark Side of Insulin

Open access
Sherwin, Robert S. · 2008 · Diabetes
Cited by 55

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

think it's remarkable that only a few months after Banting introduced insulin to the world of diabetes, on the heels of one of medicine's greatest discoveries, Elliot Joslin wrote, "insulin is not a cure for diabetes, but a potent preparation alike . . .for evil and for good."Today, 85 years later, with all the advances in insulin therapy, there is still a dark side to this potent preparation, and it is hypoglycemia.Hypoglycemia is the major barrier preventing insulin from achieving its full, therapeutic promise.My story begins 30 years ago.Bill Tamborlane came to me with a portable, battery-powered pump being used in pediatrics to infuse the iron-chelating drug desferrioxamine continuously via the subcutaneous route into children with thalassemia major.He hoped to use it to treat children with glycogen storage disease, a study we never performed.This relatively small pump, the Autosyringe Model AS2C, was at that time relatively unique.It had an "instant dose" button that allowed for bolus dose administration as well as the ability to deliver solutions continuously.In short, it was a "perfect" vehicle to infuse insulin in diabetes.Improved glucose control had been demonstrated earlier in the inpatient setting in type 1 diabetic patients given continuous intravenous insulin delivered at preprogrammed basal rates with increments before meals.Such systems were not practical outside of a controlled environment.This device, however, was small enough to be used for continuous subcutaneous insulin delivery.My enthusiasm for this idea was based on experiments Luigi Sacca and I performed 2 years earlier in the mid 1970s.We demonstrated that overnight basal insulin infusion in doses sufficient to normalize fasting glucose the next morning restored the ability of hyperglycemia to suppress hepatic glucose production in type 1 diabetic patients, despite their failure to release insulin (1).Those studies suggested that if insulin were delivered at more physiological basal rates (something that was not easy to achieve with the intermediate-acting insulin available at the time), it would not only provide better regulation of fasting glucose but also minimize postprandial hyperglycemia after a breakfast meal.The second study made me think that open-loop continuous insulin delivery might be relatively safe.In that study, we infused insulin to "conventionally" (which at that time was poorly) treated type 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db08-9023

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 55

Metadata

Authors
Sherwin, R. S.
Venue
Diabetes
Published
2008-09-01
Volume
57
Issue
9
Pages
2259-2268
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2123411875
Cited by
55
References
16
FWCI
4.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bringing Light to the Dark Side of Insulin. https://app.cochat.ai/papers/10.2337/db08-9023
The paper
Sherwin, R. S. (2008). Bringing Light to the Dark Side of Insulin. Diabetes. https://doi.org/10.2337/db08-9023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.